Department Of Ophthalmology 1
1. Functional tests in children with type 1 diabetes and their correlation with hemoglobin A1c levels
2. Cell technologies in retinitis pigmentosa treatment
3. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
4. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
5. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
6. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021
7. Medication Prescribing Patterns for Chronic Kidney Diseases: Analysis of Drug-Dose Adjustments, Polypharmacy, and Drug Interactions
8. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
9. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
10. Cardiovascular and genetic determinants of platelet high responsiveness: results from the Gutenberg Health Study
11. Impact of cyclosporine A on the progression of ocular surface diseases: treatment efficacy and potential complications
12. Impact of cyclosporine A on the progression of ocular surface diseases: treatment efficacy and potential complications
13. Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
14. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
15. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
16. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
17. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
18. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
19. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
20. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
21. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
22. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
23. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
24. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
25. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
26. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
27. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
28. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
29. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
30. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
31. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
32. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
33. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
34. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
35. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
36. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
37. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
38. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
39. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
40. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
41. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
42. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
43. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
44. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
45. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
46. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
47. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
48. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
49. Retinoblastoma outcomes in Europe: a prospective analysis of 483 patients from 40 countries
50. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
1 2 3 4